Compare Emerson Electric Co. (EMR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Recursion Pharmaceuticals Inc — how do they compare? Emerson Electric Co. trades at $165 (market cap $91.69B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Emerson Electric Co. is far larger — about 50.7× Recursion Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EMR | RXRX | |
|---|---|---|
Market Cap | $91.69B | $1.81B |
Sector | Industrials | Health |
52-Week High | $164.38 | $6.79 |
52-Week Low | $123.30 | $2.84 |
Enterprise Value | $102.77B | $1.33B |
Dividend Yield | 1.35% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
